---
source_url: https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/male_sexual_dysfunction
content_type: therapeutic_choices
document_id: male_sexual_dysfunction
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:41.145375Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: male_sexual_dysfunction.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types therapeutic_choices
  note: Requires valid CPS access credentials
---

# Male Sexual Dysfunction

### Male Sexual Dysfunction

|  |
| --- |
| Rosemary Basson, MD, FRCP(UK) |
| Date of Revision: May 10, 2021 |
| Peer Review Date: January 1, 2018 |


CPhA strives to provide guidance for health-care professionals on the appropriate care of all individuals. However, we recognize that in this chapter, our content is based on clinical research studies of patients who may not reflect the identity of the individual patient presenting. Other resources exist that may be helpful, such as the World Professional Association for Transgender Health‚Äôs (WPATH) Standard of Care. When the term ‚Äúmen‚Äù or ‚Äúmale‚Äù is used in the text, it is used to maintain accuracy with what is reported in the clinical literature. We are aware these terms are not inclusive of all patients.

#### Introduction

This chapter addresses erectile dysfunction, premature ejaculation, delayed ejaculation and low sexual desire. A careful sexual history is required to distinguish these 4 conditions since more than 1 may be present in a single patient.

Erectile dysfunction (ED) is the inability to obtain or maintain an erection sufficiently firm for satisfactory sexual activity on all or almost all occasions. Addressing sexual function is an integral part of general medical assessment, not only in patients with chronic illness‚Äã[^[1]] but in apparently healthy patients, as impairment can signal serious disease. Of note is the frequency with which vascular ED precedes evidence of coronary artery disease‚Äã[^[2]] and is a potent predictor of all-cause mortality, cardiovascular death, MI, stroke and heart failure in individuals with cardiovascular disease.‚Äã[^[3]] As vascular ED affects all erections, all patients should be asked about their ability to obtain or maintain erections.‚Äã[^[4]] There is a strong multidimensional relationship between ED, coronary artery disease and depression such that the presence of 1 of the triad necessitates inquiry about the other 2.‚Äã[^[5]] Successful treatment of ED improves self-esteem, confidence, symptoms of depression and sexual relationships.‚Äã[^[6]]

Premature ejaculation (PE) is defined as ejaculation that occurs sooner than desired, causing the individual distress. Although orgasm and ejaculation are separate physiological events, they occur simultaneously even when delayed by medication. PE may be acquired or lifelong.

Delayed ejaculation is a marked delay or inability to achieve ejaculation despite the desire to do so and despite adequate sexual stimulation. Prevalence is unclear because the definition lacks precision. It is the least common sexual complaint in patients <50 years of age but incidence increases significantly with age.

Low sexual desire, referred to in the DSM-5 as male hypoactive sexual desire disorder (MHSDD), is a persistent or recurrent lack of sexual thoughts, fantasies and desire. However, it is well recognized in people of all genders.‚Äã[^[7]] Depression, low testosterone, anxiety, insomnia, age and insufficient physical activity are associated with MHSDD.‚Äã[^[8]]

#### Goals of Therapy



#### Investigations

Assessment and management of erectile dysfunction is presented in Figure 2.

Obtain details of patient‚Äôs chief complaint and psychosexual history (see Table 1) (including from a partner, if applicable), with attention to:



|  |
| --- |
| People can have low sexual desire and difficulties with erections, reaching orgasm too quickly, too slowly or not at all. What are your main concerns?For how long have you had these difficulties?Do you have sexual thoughts or fantasies? If so, have they reduced markedly? Do you have the desire to self-stimulate/masturbate? Do you become aroused mentally if you see or hear something erotic? How sexually excited (in your mind) are you when having partnered sex?On a scale of 1/10‚Äì10/10 where 1/10 is a flaccid penis, 10/10 is completely firm and erect and 6/10 allows (but only just allows) intercourse, how firm are erections when you awaken from sleep (typically deep sleep), self-stimulate, have sexual play with a partner, attempt intercourse, as intercourse proceeds?Your experience of orgasm‚Äîhas that recently changed?Are you reaching ejaculation‚Äîand has that recently changed?If you are having sexual activity with a partner, how rewarding is it on the occasions it is still occurring or when it was occurring?Despite these difficulties, are you still sexually active alone? with a partner? how often?Are the concerns with erection or ejaculation present with self-stimulation?What are your thoughts and feelings during partnered sex? (when the concerns about low desire, erection or ejaculation apply only to partnered sex)Do you feel your partner(s) experience(s) their own sexual difficulties? Do they think that they do? Would I be able to interview them? Are they in agreement with getting help for your sexual function and reinstituting sexual activity including intercourse, if desired?What effects have these difficulties had on you, on your relationships and on your partner(s)? |


| Clues in Sexual History | Potential Etiologic Factors |
| --- | --- |
| Sleep-induced and self-stimulated erections are firmer than erections with sexual partner(s) | Psychological factors: intrapersonal (e.g., insecurity, perfectionism, distractions, depression); interpersonal (difficulties within relationships); non-erotic sexual context |
| Premature ejaculation with partner(s) but slower when self-stimulated | Psychological factors: anxiety |
| Decreased sexual desire that causes distress to the patient (fewer sexual thoughts and fantasies) | Depression, low testosterone, stress, increased prolactin, medications, psychodynamic issues, e.g., a learned response not to feel emotions generally |
| Little desire for partnered sex but ongoing self-stimulation with or without viewing pornographic material | Intimacy difficulty‚Äînot strictly sexual dysfunction |
| Ejaculation delayed | Drug effect, low testosterone, advanced age with erection augmentation by drugs |
| Ejaculation delayed only with partner(s) | Psychological factors: intimacy difficulty; own method of self-stimulation different from partnered sex |
| Ejaculation early and painful | Prostatitis, other lower urological tract problems |
| Decreased orgasm intensity | Drug effect, depression, low testosterone |
| Erectile dysfunction generalized and lifelong in younger individuals | Congenital or past traumatic vascular damage, occasionally amenable to microvascular surgery |


Gather medical history with attention to:



| Sexual Disorder | Potential Drug Causes |
| --- | --- |
| Erectile dysfunction | 5-alpha reductase inhibitorsacetazolamidealcohol (acute)alcohol (chronic)alpha-blockersanti-androgensbarbituratescarbamazepine | cimetidineclofibrateclonidinedigoxinGnRH analoguesketoconazolelithiumMAOIs | metoclopramideopioidsphenothiazinesphenytoinspironolactoneSSRIsthiazide diureticstricyclic antidepressants |
| Delayed ejaculation | 5-alpha reductase inhibitorsalpha-blockers | antipsychotics | SSRIs |
| Male hypoactive sexual desire | 5-alpha reductase inhibitorsalcohol (chronic)anti-androgensbarbituratesbeta-blockers | carbamazepineGnRH analoguesketoconazoleMAOIsopioids | phenytoinspironolactoneSSRIstricyclic antidepressants |


gonadotropin-releasing hormone

monoamine oxidase inhibitor

selective serotonin reuptake inhibitor

| Grade of Risk | Categories of Cardiovascular Disease | Management Recommendations |
| --- | --- | --- |
| Low risk | ‚Ä¢Asymptomatic, <3 major risk factors for CAD excluding age and gender‚Ä¢Controlled hypertension‚Ä¢Mild, stable angina‚Ä¢Post successful coronary revascularization‚Ä¢Uncomplicated past MI (>6‚Äì8 wk)‚Ä¢Mild valvular disease‚Ä¢LVD/HF (NYHA Class I)‚Ä¢Pericarditis‚Ä¢Mitral valve prolapse‚Ä¢Atrial fibrillation with controlled ventricular response | ‚Ä¢Primary-care management‚Ä¢Consider all first-line therapies‚Ä¢Reassess at regular intervals (6‚Äì12 months) |
| Intermediate risk | ‚Ä¢Asymptomatic, ‚â•3 major risk factors for CAD, excluding gender‚Ä¢Moderate, stable angina‚Ä¢Recent MI (2‚Äì6 wk)‚Ä¢LVD/HF (NYHA Class II)‚Ä¢Noncardiac sequelae of atherosclerotic disease, e.g., stroke, peripheral vascular disease | ‚Ä¢Evaluation by a cardiologist prior to initiation of any therapy for erectile dysfunction, due to risk of myocardial ischemia during sexual activity and orgasm‚Ä¢Specialized CV testing, e.g., ETT, echocardiogram‚Ä¢Restratification into high risk or low risk based on the results of CV assessment |
| High risk | ‚Ä¢Unstable or refractory angina‚Ä¢Uncontrolled hypertension‚Ä¢LVD/HF (NYHA Class III/IV)‚Ä¢Recent MI (<2 wk), stroke‚Ä¢High-risk arrhythmias‚Ä¢Obstructive hypertrophic cardiomyopathies‚Ä¢Moderate/severe valvular disease | ‚Ä¢Priority referral for specialized CV management‚Ä¢Treatment for sexual dysfunction to be deferred until cardiac condition stabilized and dependent on specialist recommendations |


coronary artery disease

heart failure

exercise tolerance test

left ventricular dysfunction

myocardial infarction

New York Heart Association

A physical examination is not required for a healthy patient with MHSDD. Perform physical examination for generalized ED, with attention to:



Laboratory investigations with attention to:



#### Erectile Dysfunction

#### Therapeutic Choices

#### Nonpharmacologic Choices

Address sexual avoidance by reminding patients and their partner(s) that reinstating sexual intimacy requires effort:



Address lack of subjective sexual arousal:



Address lifestyle factors:



Vacuum erection devices (VEDs), also known as vacuum constrictive devices, create a vacuum and draw venous blood back into the penis. The blood is then trapped by the use of a retaining band around the base of the penis to attain adequate firmness for intercourse. There is a learning curve with the use of VEDs. Warn patients that the tightness of the retention band is critical and the band must be removed within 30 minutes after being applied. Some individuals cannot tolerate the degree of tightness required. Any condition that predisposes to priapism (e.g., leukemia, polycythemia, myelofibrosis, sickle cell disease) is a contraindication to the use of a VED, as is warfarin therapy or other causes of increased INR.

#### Pharmacologic Choices

Table 6 details the drugs used in the management of ED.

#### Treatment of Underlying Causes

Although research is limited, in clinical practice combining psychological treatment with PDE5 inhibitors is common and evidence suggests that the combination is better than either treatment alone.‚Äã[^[18]] See Depression for more information on psychological interventions.

Treating cardiovascular risk factors with statins may benefit ED with or without the use of PDE5 inhibitors.‚Äã[^[19]] See Dyslipidemias for more information on statins.

#### Phosphodiesterase Type 5 Inhibitors

PDE5 inhibitors include sildenafil, tadalafil and vardenafil. Given their safety, efficacy and oral administration, they are the drugs of first choice for ED, including antidepressant-induced ED.‚Äã[^[20]]‚Äã[^[21]]‚Äã[^[22]] PDE5 inhibitors enhance an erection that is partially developing as a result of effective sexual stimulation and mental sexual arousal (or reflex erection in patients with spinal cord injury). There is less benefit in patients with diabetes; some evidence supports the addition of folic acid 5 mg daily to increase endothelial nitric oxide production.‚Äã[^[23]]

Duration of action is longest with tadalafil (up to 36 hours); however, the effect of sildenafil‚Äã[^[24]] and vardenafil‚Äã[^[25]] may last longer (8‚Äì12 hours) than previously thought. Vardenafil and sildenafil have some affinity for PDE6 in the retina, accounting for occasional visual side effects. Tadalafil has some affinity for PDE11A, which may underlie myalgia associated with this drug. Absorption of sildenafil is delayed by high-fat meals. A meta-analysis suggests that sildenafil is the most effective PDE5 inhibitor and tadalafil is the best tolerated.‚Äã[^[26]]

Contraindications to the use of PDE5 inhibitors include concurrent use of nitrates, symptomatic hypotension (PDE5 inhibitors are mildly hypotensive drugs), any condition in which even a slight lowering of systemic pressure is poorly tolerated (e.g., conditions restricting aortic outflow and volume depletion states), previous priapism and conditions predisposing to priapism (e.g., leukemia, polycythemia, myelofibrosis and sickle cell disease).

Careful concomitant use of PDE5 inhibitors with selective alpha-blockers (alfuzosin, tamsulosin) may benefit ED and lower urinary tract symptoms (LUTS) more than either drug alone.‚Äã[^[27]]‚Äã[^[28]] Caution is needed when using nonselective alpha-blockers due to increased risk of hypotension when combined with PDE5 inhibitors.

Daily dosing of PDE5 inhibitors may improve erectile recovery after bilateral nerve-sparing radical prostatectomy.‚Äã[^[29]]

#### Prostaglandin E1 Analogues

#### Alprostadil Intracavernosal Injection

If sufficient corporal erectile tissue is still present, injected alprostadil will cause erections even in the absence of mental sexual arousal.‚Äã[^[30]]

Because alprostadil directly stimulates nociceptors, the technique, dose and dilution are critical for efficacy, safety and comfort of erection. Proper dilution and measurement of the dose are particularly important in neurogenic ED, which often requires doses of only 1‚Äì3 mcg. Doses up to 40‚Äì60 mcg may be needed for vascular ED.‚Äã[^[30]] Priapism (a persistent and painful erection lasting >4 hours in the absence of sexual stimulation or desire) is most commonly caused by intracavernosal injections. Priapism is considered a urologic emergency and should be treated quickly (within hours of presentation) to avoid permanent penile damage. Risk of developing priapism is minimized by slow and careful dose titration of injected drugs.

Contraindications to the use of intracavernosal alprostadil include anticoagulation, previous priapism, symptomatic thrombocytopenia and conditions predisposing to priapism, e.g., leukemia, polycythemia, myelofibrosis, sickle cell disease and valve lesions with significant risk of subacute bacterial endocarditis.

#### Alprostadil by Urethral Instillation

Instilling alprostadil in the form of a pellet into the urethra allows the drug to enter the corpus spongiosum. Retrograde venous passage from spongiosum to cavernosa is unpredictable and depends on the individual's venous anatomy.‚Äã[^[30]] Therefore, a trial of intraurethral alprostadil pellets is necessary to determine efficacy in a particular patient.

By entering the communicating veins between the corpora, the drug is introduced into the systemic circulation, and hypotensive systemic side effects are possible.‚Äã[^[30]]

Contraindications to the use of intraurethral alprostadil include symptomatic hypotension, previous priapism, conditions predisposing to priapism (e.g., leukemia, polycythemia, myelofibrosis and sickle cell disease) and distal urethral pathology.

#### Premature Ejaculation

#### Therapeutic Choices

#### Nonpharmacologic Choices

The following sex therapy techniques may benefit patients interested in nonpharmacologic treatment options. They are not appropriate for individuals in a partnered relationship for whom referral for relationship counselling is the appropriate therapy.



Address possible sequelae of PE in both the patient and their partner(s), if appropriate (see Table 5).

|  |
| --- |
| Low sexual self-confidence (which creates more anxiety, compounding premature ejaculation and possibly provoking erectile dysfunction)Arousal, desire or orgasmic disorder resulting from rushing on to (brief) intercourse, or simply discontinuing sexual engagement as soon as the early ejaculation occursIntercourse itself never resulting in orgasm for partner(s) |


#### Pharmacologic Choices

Clinically significant delay in ejaculation may be achieved with regular daily dosing of citalopram (20‚Äì40 mg), clomipramine (12.5‚Äì50 mg), paroxetine (10‚Äì40 mg) or sertraline (50‚Äì200 mg), or on-demand therapy with clomipramine, paroxetine or sertraline 3‚Äì6 hours before sexual activity.‚Äã[^[31]] Regular daily dosing is considered more effective than on-demand treatment and may require 2‚Äì3 weeks for full therapeutic benefit.‚Äã[^[31]] Most common side effects with these agents include fatigue, nausea, diarrhea, decreased sexual desire and erectile dysfunction. Relapse is likely when medication is discontinued. Combining pharmacologic and behavioural techniques is recommended to prolong benefit and ultimately allow gradual withdrawal of medication.

PDE5 inhibitors may be beneficial in the treatment of PE and possibly more effective than SSRIs. Ejaculation is delayed most effectively by a combination of PDE5 inhibitors and SSRIs.‚Äã[^[32]]‚Äã[^[33]]

Although not generally recommended, intracavernosal therapy in those with severe PE may improve partner satisfaction due to erectile persistence after ejaculation.

Numbing the penile skin with local anesthetic can be effective in delaying ejaculation but reinforces the patient‚Äôs inability to recognize lower states of sexual arousal.

Despite some evidence of benefit in patients with premature ejaculation, prescribing tramadol off-label for this indication is not recommended given the risk of dependence.‚Äã[^[34]]

#### Delayed Ejaculation

#### Therapeutic Choices

#### Nonpharmacologic Choices



#### Pharmacologic Choices

Review the patient's medications and, if possible, change any drugs that may be causing the dysfunction, e.g., 5-alpha reductase inhibitors, alpha-blockers, antipsychotics, SSRIs (see Table 3).

#### Male Hypoactive Sexual Desire Disorder

#### Therapeutic Choices

#### Nonpharmacologic Choices



![](images/malesexualdysfunction_modmalsexrescyc.gif)


**AI Image Description:**
The image is a flowchart illustrating the cycle of sexual desire and intimacy. Here is a detailed description of its contents:

1. **Central Element:**
   - **Seemingly ‚Äúspontaneous‚Äù desire**: This is the central point of the flowchart, indicating a neutral state with many motivations, including enhancing emotional intimacy.

2. **Flowchart Pathways:**
   - **From "Seemingly 'spontaneous' desire" to "Sexual stimuli":**
     - Arrows indicate that this state leads to seeking out and being receptive to sexual stimuli.
   
   - **From "Sexual stimuli" to "Sexual arousal":**
     - Biological and psychological factors affect the processing of stimuli, leading to sexual arousal.
   
   - **From "Sexual arousal" to "Sexual desire":**
     - Sexual arousal progresses to sexual desire.
   
   - **From "Sexual desire" to "Enhanced intimacy":**
     - This transition is associated with more arousal and pleasure, resulting in a positive outcome emotionally and physically.
   
   - **From "Enhanced intimacy" back to "Seemingly 'spontaneous' desire":**
     - Enhanced intimacy feeds back into the central state, completing the cycle.

3. **Annotations:**
   - Each transition is annotated with descriptions of the processes or outcomes involved, such as the influence of biological and psychological factors or the enhancement of intimacy.

This flowchart represents the cyclical nature of sexual desire and intimacy, highlighting the interplay between emotional and physical factors.

*AI-generated description for accessibility and content understanding*


#### Pharmacologic Choices

Testosterone replacement therapy may be effective for patients experiencing MHSDD associated with endogenous testosterone deficiency;‚Äã[^[35]] however, the role of testosterone supplementation is uncertain in individuals who are not clearly hypogonadal.‚Äã[^[36]]

Correction of hyperprolactinemia is expected to benefit low desire.‚Äã[^[37]]

#### Therapeutic Tips



#### Algorithms

![](images/malesexualdysfunction_assmanacqeredys.gif)


**AI Image Description:**
The image is a flowchart designed to guide the management of erectile dysfunction (ED) based on different scenarios and factors. Here is a detailed description of its contents:

1. **Initial Question:**
   - "Erections with partner better than erections alone or from sleep?"
   - Options: No / Yes

2. **If No:**
   - **Address Psychological Issues**
   - **ED Not Resolved:**
     - Question: "On a scale of 1‚Äì10 (1 is flaccid penis and 10 is completely firm and erect) are there ever self-stimulated and/or nocturnal erections that would be rated 8‚Äì10?"
     - Options: Yes / No
     - **If Yes:**
       - Continue addressing psychological issues and having addressed cardiac safety, add PDE5 inhibitor, alprostadil, or VED.
     - **If No:**
       - Continue addressing psychological issues; conduct physical exam, medical and sexual history.

3. **If Yes:**
   - **Are There Reversible Factors?**
     - (See Table 2, Table 3)
     - Consider: Medical history, Sexual history, Physical exam
     - Options: No / Yes
     - **If No:**
       - Assess safety of resumed sexual activity
       - Address sexual context
       - **Are nitrates or alpha-blockers prescribed or likely needed?**
         - Options: Yes / No
         - **If Yes:**
           - Alprostadil VED
         - **If No:**
           - **PDE5 inhibitors likely to benefit (mental arousal & intact nerves required)?**
             - Options: Yes / No
             - **If Yes:**
               - PDE5 inhibitor
             - **If No:**
               - Alprostadil VED
     - **If Yes:**
       - Address reversible factors

**Key Terms:**
- **PDE5 inhibitor:** A type of medication used to treat erectile dysfunction.
- **Alprostadil:** A drug that can be used to treat ED, often administered via injection or suppository.
- **VED:** Vacuum Erection Device, a mechanical way to produce an erection.

This flowchart provides a structured approach to diagnosing and treating erectile dysfunction by considering psychological, medical, and situational factors.

*AI-generated description for accessibility and content understanding*


erectile dysfunction

phosphodiesterase type 5

vacuum erection device

#### Drug Table


**Drug Class: PDE5 Inhibitors**


**Drug Class: PGE1 Analogues**

| Drug/‚ÄãCost[a] | Dosage | Adverse Effects | Drug Interactions | Comments |
| --- | --- | --- | --- | --- |
| **sildenafil** (Viagra, Sildenafil, other generics) | 50‚Äì100 mg PO 30‚Äì60 min before sexual activity. Maximum 100 mg per 24 h. Not for daily useStart at 25 mg if patient is also using CYP3A4 inhibitors, >65 y or has renal/liver dysfunction | Headache, flushing, dyspepsia, nasal congestion, transient visual disturbances, dizziness, skin rash, priapism (rare), permanent vision loss (rare).Sudden sensorineural hearing loss and increased hearing thresholds at higher frequencies have been reported in users of PDE5 Inhibitors. | Contraindicated with nitrates (seek emergency care if chest pain present within 24‚Äì48 h of taking PDE5 inhibitor; not to be given for 5 days after stopping long-acting nitrates).May cause hypotension if used with nonselective alpha-blockers, e.g., doxazosin, prazosin.CYP3A4 inhibitors can significantly decrease metabolism of the PDE5 inhibitor.CYP3A4 inducers may decrease efficacy of the PDE5 inhibitor. | Onset of action may be as early as 15 min. Duration of action may be up to 12 h. Efficacy dependent on mental arousal. Dyspepsia and transient visual disturbances (impaired blue/green discrimination, blurred vision or increased light sensitivity) >10% with doses of 100 mg. Use with caution in retinitis pigmentosa. High-fat meal delays absorption. |
| **tadalafil** (Cialis, generics) | Once-a-day dosing: 2.5‚Äì5 mg daily POOn-demand dosing: 10‚Äì20 mg PO 60 min before sexual activity. Maximum 20 mg every 36‚Äì48 hStart at 2.5‚Äì5 mg if patient is also using strong CYP3A4 inhibitors, >65 y or has renal/liver dysfunction | Headache, flushing, dyspepsia, nasal congestion, myalgia, back pain, visual disturbances (rare), permanent vision loss (rare).Sudden sensorineural hearing loss and increased hearing thresholds at higher frequencies have been reported in users of PDE5 inhibitors. | Contraindicated with nitrates (seek emergency care if chest pain present within 24‚Äì48 h of taking PDE5 inhibitor; not to be given for 5 days after stopping long-acting nitrates).May cause hypotension if used with nonselective alpha-blockers, e.g., doxazosin, prazosin.CYP3A4 inhibitors can significantly decrease metabolism of the PDE5 inhibitor.CYP3A4 inducers may decrease efficacy of the PDE5 inhibitor. | Onset of action within 30‚Äì60 min. Efficacy dependent on mental arousal. Duration of effect up to 36 h. Daily use is not recommended for those with severe renal impairment. Desirable in those who want more freedom in timing their sexual activity. No delay in absorption after food. Not recommended in severe hepatic impairment. |
| **vardenafil** (Levitra, Staxyn, generics) | Levitra (film-coated tablets): 10‚Äì20 mg PO 30‚Äì60 min before sexual activity. Maximum 20 mg per 24 h Staxyn (orally disintegrating tablets): 10 mg dissolved on tongue 45‚Äì90 min before sexual activity. Maximum 10 mg per 24 hNot for daily useStart with 5 mg film-coated tablets if patient is also using CYP3A4 inhibitors, >65 y or has liver dysfunction | Headache, flushing, dyspepsia, rhinitis, sinusitis, transient visual disturbances. Slight prolongation of QTc interval.Sudden sensorineural hearing loss and increased hearing thresholds at higher frequencies have been reported in users of PDE5 inhibitors. | Contraindicated with nitrates (seek emergency care if chest pain present within 24‚Äì48 h of taking PDE5 inhibitor; not to be given for 5 days after stopping long-acting nitrates).May cause hypotension if used with nonselective alpha-blockers, e.g., doxazosin, prazosin.CYP3A4 inhibitors can significantly decrease metabolism of the PDE5 inhibitor.CYP3A4 inducers may decrease efficacy of the PDE5 inhibitor.Do not use with quinidine, procainamide, amiodarone or sotalol due to increased risk of QTc prolongation. | Onset of action may be as early as 10 min. Duration of action up to 12 h. Efficacy dependent on mental arousal. Fatty meals decrease maximum blood concentration. Do not use in patients with congenital long QT syndrome. Orally disintegrating tablets and film-coated tablets are not bioequivalent. |
| **alprostadil (intracavernosal injection)** (Caverject) | Neurogenic ED: start with 1.25 mcg. If needed, may increase to 2.5 mcg then by 5 mcg increments to a maximum of 60 mcg Vascular, psychogenic or mixed ED: start with 2.5 mcg and titrate to responseSevere vascular ED may require up to 40‚Äì60 mcgErection duration up to 1 h | Penile pain, hematoma, ecchymosis, penile fibrosis, priapism (rare). | Increased risk of hypotension if combined with alcohol, antihypertensive agents or vasodilators. | Use 5‚Äì10 min prior to sexual activity. Do not use more than once daily or 3 times per week, at least 24 h between each dose. Caution regarding needle stick injury and risk of STI transmission. Stress strict sterile technique, especially if known risk of endocarditis. Stress one-time use of needle and syringe provided in Caverject kit. The initial dose is determined during self-injection teaching in the physician's office. |
| **alprostadil (intraurethral pellet)** (MUSE) | 250‚Äì1000 mcg 10‚Äì30 min before sexual activity. Dose depends on venous anatomy rather than ED etiology. Onset of effect in 5‚Äì10 min | Penile pain, dizziness, syncope (rare), priapism (rare). | Additive hypotension with antihypertensives. | Do not use more than once per 24-h period. Monitor BP during in-office titration to detect asymptomatic hypotension. |


**ü´ò Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI description pending for: images/kidney.gif -->

blood pressure

erectile dysfunction

sexually transmitted infection

#### Suggested Readings

**Erectile Dysfunction**

Bella AJ, Lee JC, Carrier S et al. 2015 CUA Practice guidelines for erectile dysfunction. *Can Urol Assoc J* 2015;9(1-2):23-9.

Hatzimouratidis K, Salonia A, Adaikan G et al. Pharmacotherapy for erectile dysfunction: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). *J Sex Med* 2016;13(4):465-88.

Katsiki N, Wierzbicki AS, Mikhailidis DP. Erectile dysfunction and coronary heart disease. *Curr Opin Cardiol* 2015;30(4):416-21.

**Male Hypoactive Sexual Desire Disorder**

DeRogatis L, Rosen RC, Goldstein I et al. Characterization of hypoactive sexual desire disorder (HSDD) in men. *J Sex Med* 2012;9(3):812-20.

Martin S, Atlantis E, Wilson D et al. Clinical and biopsychosocial determinants of sexual dysfunction in middle-aged and older Australian men. *J Sex Med* 2012;9(8):2093-103.

**Premature Ejaculation**

Basson R, Schultz WW. Sexual sequelae of general medical disorders. *Lancet* 2007;369(9559):409-24.

Binik YM, Hall KSK, editors. *Principles and practice of sex therapy*. 5th ed. New York (NY): Guilford Press; 2014.

Chung E, Gilbert B, Perera M et al. Premature ejaculation: a clinical review for the general physician. *Aust Fam Physician* 2015;44(10):737-43.

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/male_sexual_dysfunction](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/male_sexual_dysfunction)  
**Content Type:** therapeutic_choices  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *male_sexual_dysfunction*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/male_sexual_dysfunction


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 ‚Ä¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/male_sexual_dysfunction)*
